Home > Insider Trading > Aktis Oncology Inc. > Profile

Aktis Oncology Inc. (AKTS)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

Sector: Pharmaceutical Preparations

Insider Roster

Eli Lilly & Co, 2026-01-15
Todd Foley, 2026-01-14
Mpm Oncology Innovations Fund Gp Llc, Large Shareholder, 2026-01-14

Eli Lilly & Co, 2026-01-15
Todd Foley, 2026-01-14
Mpm Oncology Innovations Fund Gp Llc, Large Shareholder, 2026-01-14
Mpm Bioventures 2018 Llc, Large Shareholder, 2026-01-14
Mpm Bioventures 2018 Gp Llc, Large Shareholder, 2026-01-14
Mpm Asset Management Investors Bv2018 Llc, Large Shareholder, 2026-01-14
Mpm Bioventures 2018, L.p., 2026-01-14
Mpm Bioventures 2018 (B), L.p., Large Shareholder, 2026-01-14
Mpm Oncology Innovations Fund Lp, Large Shareholder, 2026-01-14
Luke Evnin, Large Shareholder, 2026-01-14
Oncology Impact Private Investment Fund 2, L.p., Large Shareholder, 2026-01-14
Mpm Asset Management Llc, Large Shareholder, 2026-01-14
Ansbert Gadicke, 2026-01-14
Ecor1 Capital, Llc, Director, 2026-01-13
Oleg Nodelman, Director, 2026-01-13
Vida Ventures Ii-A, Llc, 2026-01-12
Vida Ventures Ii, Llc, 2026-01-12
Susan Helen Kim, 2026-01-12
Mitchell Lloyd Segal, 2026-01-12
D. Kyle Kuvalanka, Chief Financial Officer, 2026-01-09
Ken Herrmann, 2026-01-09
Matthew Roden, President and Ceo, 2026-01-09
Shulamit Ron-Bigger, Chief Operating Officer, 2026-01-09
L Paul Feldman, Chief Scientific Officer, 2026-01-09
Akos Czibere, Chief Medical Officer, 2026-01-09
A. Michael Sherman, 2026-01-09
Mary Thistle, 2026-01-09

Show All Insiders (27)

Insider Trading: Purchases See All

Insider	Price	Amount	Total Value	Remaining Holdings	Date	Form 4
Foley	$18.00	232,870	$4,191,660.00	4,235,403	2026-01-12	Filing
Mpm	$18.00	1,112,777	$20,029,986.00	10,260,064	2026-01-12	Filing
Gadicke	$18.00	1,112,777	$20,029,986.00	10,260,064	2026-01-12	Filing
Ecor1 Director	$18.00	144,443	$2,599,974.00	347,305	2026-01-12	Filing
Ecor1 Director	$18.00	2,077,779	$37,400,022.00	4,348,658	2026-01-12	Filing

News See All

Akoustis Technologies, Inc. (NASDAQ:AKTS) Q3 2024 Earnings Call Transcript

Operator: Good day, ladies and gentlemen, and welcome to the Akoustis Technologies Fiscal 2024 Third Quarter Conference Call. As a reminder, this conference is being recorded.

Keep Reading →

May 14th, 2024 - News Transcripts

Akoustis Technologies, Inc. (NASDAQ:AKTS) Q2 2024 Earnings Call Transcript

Akoustis Technologies, Inc. misses on earnings expectations. Reported EPS is $-0.19 EPS, expectations were $-0.18.

Keep Reading →

February 14th, 2024 - News Transcripts

Akoustis Technologies, Inc. (NASDAQ:AKTS) Q1 2024 Earnings Call Transcript

Operator: Good day, ladies and gentlemen, and welcome to the Akoustis Technologies Fiscal 2024 First Quarter Conference Call. As a reminder, this conference call is being recorded.

Keep Reading →

November 14th, 2023 - News Transcripts

Akoustis Technologies, Inc. (NASDAQ:AKTS) Q4 2023 Earnings Call Transcript

Operator: Good day, ladies and gentlemen, and welcome to the Akoustis Technologies Fiscal 2023 Fourth Quarter Conference Call. As a reminder, this conference call is being recorded.

Keep Reading →

September 7th, 2023 - News Transcripts

Akoustis Technologies, Inc. (NASDAQ:AKTS) Q3 2023 Earnings Call Transcript

Operator: Good day, ladies and gentlemen, and welcome to the cTechnologies Fiscal 2020 Third Quarter Conference Call. As a reminder, this conference call is being recorded.

Keep Reading →

May 10th, 2023 - News Transcripts

12 Most Promising Growth Stocks According to Analysts

Which stocks perform better? Growth or value? This age-old growth versus value debate has been around ever since people started investing in the stock markets.

Keep Reading →

February 25th, 2023 - Hedge Funds News

12 Most Promising Micro-Cap Stocks According to Analysts

In this article, we will take a look at the 12 most promising micro-cap stocks according to analysts.

Keep Reading →

February 17th, 2023 - Hedge Funds News

Akoustis Technologies, Inc. (NASDAQ:AKTS) Q2 2023 Earnings Call Transcript

Operator: Good day, ladies and gentlemen, and welcome to the Akoustis Technologies Fiscal 2023 Second Quarter Conference Call. As a reminder, this conference call is being recorded.

Keep Reading →

February 8th, 2023 - News Transcripts

Akoustis Technologies, Inc. (NASDAQ:AKTS) Q1 2023 Earnings Call Transcript

Operator: Good day, ladies and gentlemen, and welcome to the Akoustis Technologies Fiscal 2023 First Quarter Conference Call. As a reminder, this conference call is being recorded.

Keep Reading →

December 29th, 2022 - News Transcripts

Is Akoustis Technologies, Inc. (AKTS) A Good Stock To Buy?

After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed...

Keep Reading →

December 2nd, 2020 - Hedge Funds News

Click here to See All News

Insider Monkey Quarterly Strategy

+498.7% Insider Monkey Quarterly Strategy

+195% Benchmark50% S&P 500 ETF and 50% Russell 2000 ETF

400%

200%

Returns since its inception in May 2014 (through February 18th, 2026)

Subscribe Now

30 day money back guarantee. Cancel anytime.

Follow Insider Monkey at Twitter

Hedge Fund Resource Center

How to Best Use Insider Monkey to Increase Your Returns
Why Track Hedge Funds?
Download a Free Edition!
Why You Should DUMP Your Hedge Funds
6 Things You Didn't Know About Hedge Funds